newsfilter
← Latest News
GlobeNewswire·

Anteris Technologies Announces Results for the Third Quarter of 2026

  • Anteris Technologies Global Corp. reported financial results for the quarter ended September 30, 2026, & provided a corporate update.
  • The PARADIGM Trial continued enrollment across active sites in the U.S., Canada, Denmark, the Netherlands, & France.
  • Following the quarter, the trial received regulatory clearance from Germany's BfArM & expanded in Australia after HREC approval & TGA authorization.
  • Anteris assumed occupancy of the Northcross facility in Minnesota to scale production of the DurAVR THVs & ComASUR Delivery System.
  • Brent Moen was appointed Chief Financial Officer effective September 11, 2026, to support financial priorities & governance.
  • Net operating cash outflows for the quarter totaled $22.9 million, driven by clinical, regulatory, & manufacturing costs.
  • R&D expenses reached $21.3 million due to manufacturing scaling, quality validation, expanded headcount, & trial-related patient enrollment.
  • The PARADIGM Trial is a prospective randomized study evaluating the safety & effectiveness of the DurAVR THV against commercially available TAVRs in approximately 1,000 patients.
  • The DurAVR THV is a biomimetic, balloon-expandable valve using FDA-cleared ADAPT tissue & remains for investigational use only.
  • Anteris is a global healthcare company founded in Australia with a significant presence in Minneapolis focused on structural heart disease solutions.
Company
Anteris Technologies Pty Ltd
Keywords
Australian Stock Exchange:AVR.AX, Anteris Technologies Pty Ltd, Anteris Technologies, 10-Q, Third Quarter Results, Q3 Financial Results, PARADIGM Trial, DurAVR THV, Corporate Update